NCT03793322 is a Phase 1 clinical trial of Indocyanine-Green(ICG) in Hepatocellular Carcinoma, sponsored by Zhujiang Hospital.

Who is sponsoring NCT03793322?

NCT03793322 is sponsored by Zhujiang Hospital.

What drugs are being tested in NCT03793322?

Interventions in NCT03793322: Indocyanine-Green(ICG).

What condition does NCT03793322 study?

NCT03793322 studies Hepatocellular Carcinoma.

Is NCT03793322 still recruiting?

NCT03793322 is currently status unknown. Last updated 4 January 2019.

Last reviewed 2019-01-04 · How we verify

NCT03793322

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma

Status unknown Phase 1 Last updated 4 January 2019

What this trial tests

Phase 1 trial testing Indocyanine-Green(ICG) in Hepatocellular Carcinoma in 100 participants. Status unknown.

Timeline

1 January 2017

Primary endpoint
1 January 2020

31 December 2020

Quick facts

Lead sponsor	Zhujiang Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	1 January 2017
Primary completion	1 January 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Indocyanine-Green(ICG)

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Zhujiang Hospital

Who can join

Adults 18 to 80, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the feasibility of indocyanine green (ICG)-based fluorescence imaging in the detection of liver tumors. By correlating the ICG fluorescence patterns with pathologically confirmed tumors , it would be possible to use fluorescence navigation system in helping promoting oncology treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Fluorescence-guided hepatobiliary surgery with long and short wavelength fluorophores.
Lwin TM, Hoffman RM, Bouvet M. · · 2020 · cited 17× · PMID 33163512 · DOI 10.21037/hbsn.2019.09.13
Transforming Cancer Diagnosis and Therapy Through Fluorescent Hydrogels: A Review.
Masaeli E, Srinivasan S, Rajabzadeh AR. · · 2026 · cited 1× · PMID 40905474 · DOI 10.1002/adhm.202502577

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Zhujiang Hospital trials

Trials by the same sponsor.

NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03793322 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 4 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03793322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing